Holen Sie sich die Stockscreener-App
45.40
2.09%
0.93
Handel nachbörslich:
45.30
-0.10
-0.22%
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis Gains Analyst Confidence as Cancer Studies Advances - MSN
Exelixis Advances Cancer Studies with Rising Analyst Confidence - AInvest
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? - Yahoo Finance
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings - Yahoo Finance
Is Exelixis Inc. a good long term investmentSuperior profit margins - jammulinksnews.com
Is Exelixis, Inc.'s (NASDAQ:EXEL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Yahoo Finance
Lobbying Update: $480,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
Morgan Stanley Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $48 - 富途牛牛
What analysts say about Exelixis Inc. stockStrong return on investment - Autocar Professional
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner - MSN
Exelixis Inc. Stock Analysis and ForecastTremendous wealth creation - PrintWeekIndia
What drives Exelixis Inc. stock priceHigh-performance investment picks - jammulinksnews.com
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. - The Motley Fool
Teva Pharmaceutical Industries Limited shares fall 1.38% intraday after Exelixis, Inc. presents at Lucid Capital Markets. - AInvest
Exelixis Advances Cancer Treatment with New Phase 1 Study of XL309 - The Globe and Mail
Exelixis’s SWOT analysis: zanza trials key to stock’s future growth By Investing.com - Investing.com South Africa
Exelixis’s SWOT analysis: zanza trials key to stock’s future growth - Investing.com
Exelixis Insiders Sell US$12m Of Stock, Possibly Signalling Caution - simplywall.st
Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - The Globe and Mail
Truist Securities raises Exelixis stock price target to $56 on positive outlook - Investing.com Canada
Truist Lifts Price Target on Exelixis to $56 From $55, Keeps Buy Rating - MarketScreener
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - BioSpace
Press Release: Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - 富途牛牛
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com
Exelixis’ Phase 3 Trial: A New Hope for Renal Cell Carcinoma? - TipRanks
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Exelixis (EXEL) - The Globe and Mail
Barclays Remains a Hold on Exelixis (EXEL) - The Globe and Mail
Assessing Exelixis: Insights From 12 Financial Analysts - Nasdaq
Exelixis cut to sector perform at RBC as cash flows fairly valued - MSN
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance
RBC Capital Keeps Their Buy Rating on Exelixis (EXEL) - The Globe and Mail
RBC Downgrades Exelixis to Sector Perform From Outperform, Lifts Price Target to $50 From $45 - MarketScreener
Exelixis (EXEL): Why Now is the Time to Act on Strong Clinical and Financial Catalysts - AInvest
Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade) - Seeking Alpha
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock? - The Globe and Mail
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Exelixis’s SWOT analysis: stock poised for growth amid pipeline progress - Investing.com
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance
Cancer index outperforms broader markets with 13% Q2 rebound - BioWorld MedTech
Exelixis, Inc. (EXEL) Stock Analysis: Riding the Wave of 30.60% Revenue Growth in the Biotechnology Sphere - DirectorsTalk Interviews
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):